Huang Kun (Kun Huang)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 21

Top Topics

Atrial Fibrillation

Intensive Care Unit

Hodgkin Lymphoma

Top Venues

Haemophilia : the official journal of the World Federation of Hemophilia

Advances in therapy

JMIR public health and surveillance

Research and practice in thrombosis and haemostasis

This page only lists publications with an associated author ORCID identifier.

Publications

Huang Kun
Letter to the Editor Regarding "Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China". Advances in therapy 41 (4) (2024)
Huang Kun
Letter to the Editor Regarding "Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China". Advances in therapy (2024)
Huang Kun
The Need for a Bleed Type-Specific Annual Bleeding Rate in Hemophilia Studies. JMIR public health and surveillance 10 (2024)
Huang Kun
The Need for a Bleed Type-Specific Annual Bleeding Rate in Hemophilia Studies. JMIR public health and surveillance 10 (2024)
Huang Kun
Letter to the Editor Regarding "Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China". Advances in therapy 41 (4) (2024)
Huang Kun
Letter to the Editor Regarding "Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China". Advances in therapy 41 (4) (2024)
Huang Kun
The Need for a Bleed Type-Specific Annual Bleeding Rate in Hemophilia Studies. JMIR public health and surveillance 10 (2024)
Huang Kun
The Need for a Bleed Type-Specific Annual Bleeding Rate in Hemophilia Studies. JMIR public health and surveillance 10 (2024)
Huang Kun
Letter to the Editor Regarding "Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China". Advances in therapy 41 (4) (2024)
Huang Kun, Di Ai, Gang Li, Yingzi Zhen, Yan Wang, Ningning Zhang, Aihua Huo, Guoqing Liu, Zhenping Chen, Runhui Wu
Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A. Haemophilia : the official journal of the World Federation of Hemophilia 28 (6) (2022)
Jie Sun, Zekun Li, Huang Kun, Di Ai, Gang Li, Xingjuan Xie, Hao Gu, Guoqing Liu, Yingzi Zhen, Zhenping Chen, Runhui Wu
F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China. Research and practice in thrombosis and haemostasis 6 (4) (2022)
Jie Sun, Zekun Li, Gang Li, Huang Kun, Di Ai, Guoqing Liu, Wanru Yao, Xingjuan Xie, Hao Gu, Yingzi Zhen, Zhenping Chen, Runhui Wu
Low-dose immune tolerance induction in children with severe hemophilia A with high-titer inhibitors: Type of factor 8 mutation and outcomes. Research and practice in thrombosis and haemostasis 6 (7) (2022)
Huang Kun, Yingzi Zhen, Gang Li, Xinyi Wu, Zhenping Chen, Runhui Wu
Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half-life factor VIII concentrates. Research and practice in thrombosis and haemostasis 6 (2) (2022)
Zekun Li, Guoqing Liu, Wanru Yao, Zhenping Chen, Gang Li, Xiaoling Cheng, Yingzi Zhen, Di Ai, Huang Kun, Jie Sun, Man-Chiu Poon, Runhui Wu
Eradication of FIX inhibitor in haemophilia B children using low-dose immune tolerance induction with rituximab-based immunosuppressive agent(s) in China. Haemophilia : the official journal of the World Federation of Hemophilia 28 (4) (2022)
Huang Kun, Zhenping Chen, Runhui Wu
"A personalized limited sampling approach to better estimate terminal half-life of FVIII concentrates": Comment from Huang et al. Journal of thrombosis and haemostasis : JTH 20 (10) (2022)
Huang Kun, Yingzi Zhen, Gang Li, Xinyi Wu, Zhenping Chen, Runhui Wu
Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. Haemophilia : the official journal of the World Federation of Hemophilia 27 (4) (2021)
Zekun Li, Zhenping Chen, Guoqing Liu, Xiaoling Cheng, Wanru Yao, Huang Kun, Gang Li, Yingzi Zhen, Xinyi Wu, Siyu Cai, Man-Chiu Poon, Runhui Wu
Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. Research and practice in thrombosis and haemostasis 5 (5) (2021)
Huang Kun, Weiqun Xu, Min Zhou, Xiaojing Li, Zhongjin Xu, Yongjun Fang, Changgang Li, Zhenping Chen, Runhui Wu
Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study. BMJ open 11 (7) (2021)
Zekun Li, Guoqing Liu, Wanru Yao, Zhenping Chen, Gang Li, Xiaoling Cheng, Yingzi Zhen, Di Ai, Huang Kun, Man-Chiu Poon, Runhui Wu
Nephrotic syndrome in two haemophilia B children with inhibitor under low-dose immune tolerance induction combined with rituximab-based immunosuppressant protocol. Haemophilia : the official journal of the World Federation of Hemophilia 28 (2) (2021)
Huang Kun, Yingzi Zhen, Gang Li, Xinyi Wu, Runhui Wu, Zhenping Chen
Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A. Haemophilia : the official journal of the World Federation of Hemophilia 27 (3) (2021)
Huang Kun, Gang Li, Yingzi Zhen, Xinyi Wu, Zhenping Chen, Runhui Wu
Comparative pharmacokinetics of Kogenate FS and Kovaltry in 14 Chinese paediatric patients with haemophilia A: A single-centre study. Haemophilia : the official journal of the World Federation of Hemophilia 27 (2) (2020)